Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 2/20 | 0.42 |
| ▸ | DPP4 | P27487 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.38 |
| ▸ | METAP1 | P53582 | 1/20 | 0.37 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.36 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.36 |
| ▸ | ECE1 | P42892 | 2/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 1/20 | 0.34 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
| ▸ | CPA1 | P15085 | 1/20 | 0.34 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.34 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15623649 | 1.00 | TERT (0.42) | TERTDPP4ALDH1A1LMNAMAPT | |
| Acetic Acid SCHEMBL10665238 | 0.94 | ALDH1A1 (0.41) | TERTDPP4ALDH1A1LMNAMAPT | |
| Acetic Acid SCHEMBL10665240 | 0.94 | ALDH1A1 (0.41) | TERTDPP4ALDH1A1LMNAMAPT | |
| SCHEMBL15840389 | 0.86 | DPP4 (0.42) | TERTDPP4ALDH1A1LMNAMAPT | |
| SCHEMBL3088751 | 0.83 | ALDH1A1 (0.41) | DPP4ALDH1A1LMNAMAPTPTGS2 | |
| SCHEMBL8819205 | 0.82 | DPP4 (0.44) | TERTDPP4ALDH1A1LMNAMAPT | |
| SCHEMBL26291258 | 0.82 | DPP4 (0.44) | TERTDPP4ALDH1A1LMNAMAPT | |
| SCHEMBL7204776 | 0.81 | PAX8 (0.41) | TERTDPP4ECE1DPP8DPP7 | |
| SCHEMBL7204771 | 0.81 | PAX8 (0.41) | TERTDPP4ECE1DPP8DPP7 | |
| SCHEMBL22188067 | 0.81 | DPP4 (0.39) | TERTDPP4ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210147484-A1 | BICYCLIC PEPTIDE LIGANDS AND USES THEREOF | BICYCLETX LIMITED (GB) | 2021-05-20 | — | — | US | disclosed |
| WO-2021019243-A1 | HETEROTANDEM BICYCLIC PEPTIDE COMPLEX | BICYCLETX LIMITED (GB) | 2021-02-04 | — | — | WO | disclosed |
| EP-3130608-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | Daiichi Sankyo Co., Ltd. (JP) | 2017-02-15 | — | — | EP | disclosed |
| US-20170035906-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-02-09 | — | — | US | disclosed |
| CN-1143859-C | Camptothecin derivative and its preparation | ������ҩ��ʽ���� | 2004-03-31 | — | — | CN | disclosed |
| CN-1075501-C | Camptothecin derivatives, preparation method, intermediate and application | TANABE SEIYAKU CO (JP) | 2001-11-28 | — | — | CN | disclosed |
| CN-1308078-A | Camptothecin derivative and its preparation | TANADE SEIYAKU CO LTD (JP) | 2001-08-15 | — | — | CN | disclosed |
| EP-0295316-B1 | Antitumor amino acid and peptide derivatives of 1,4-bis[ (aminoalkyl and hydroxyaminoalkyl)- amino]-5,8 dihydroxyanthraquinones | AMERICAN CYANAMID CO (US) | 1995-11-08 | — | — | EP | disclosed |
| EP-0207680-B1 | CHEMICAL COMPOUNDS | ISF SOCIETA PER AZIONI (IT) | 1990-08-29 | — | — | EP | disclosed |
| US-4703054-A | Nootropic imidazolidinones | ISF, S.P.A. (IT) | 1987-10-27 | — | — | US | disclosed |
| EP-0207680-A2 | Chemical compounds | ISF SOCIETA PER AZIONI (IT) | 1987-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170035906-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | ERBB2, EGFR, LANCL2 | TERT 3082/4885DPP4 3243/4885ALDH1A1 2238/4885 |
| US-20210147484-A1 | BICYCLIC PEPTIDE LIGANDS AND USES THEREOF | VIP, NGLY1, BID | TERT 2356/4885DPP4 160/4885ALDH1A1 4861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.